Risk of serious bacterial infections in inflammatory rheumatic or bowel disease patients during biological therapies: nationwide Danish cohort study-Reference-Cited by-同舟云学术

Risk of serious bacterial infections in inflammatory rheumatic or bowel disease patients during biological therapies: nationwide Danish cohort study

Published:2025-06-25 Issue:1 Volume:57 Page:
ISSN:0785-3890
Container-title:Annals of Medicine
language:en
Short-container-title:Annals of Medicine

Author:

Platz Emma Cathrine Højberg¹²^ORCID,Laugesen Gustav Emil¹²^ORCID,Østergaard Anne Ahrens¹²^ORCID,Byg Keld-Erik³⁴^ORCID,Petersen Inge¹^ORCID,Johansen Isik Somuncu¹²^ORCID

Affiliation:

1. Department of Infectious Diseases, Odense University Hospital

2. Research Unit of Infectious Diseases, Department of Clinical Research, University of Southern Denmark

3. Department of Rheumatology, Odense University Hospital

4. Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark

Funder

The Region of Southern Denmark Research Council

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/07853890.2025.2522968

Reference40 articles.

1. European Medicines Agency. Summary of product characteristics. Remicade European Medicines Agency; 2009 [cited 2024 Apr 19]. Available from: https://www.ema.europa.eu/en/documents/product-information/remicade-epar-product-information_en.pdf

2. RADS—Rådet for Anvendelse af Dyr Sygehusmedicin. Baggrundsnotat for dyre lægemidler til behandling af kroniske inflammatoriske tarmsygdomme [The council for use of expensive hospital medication: background information on biological and synthetic targeted drugs for the use of inflammatory bowel disease]. RADS; 2017 [cited 2024 Apr 19]. Available from https://rads.dk/media/4294/bgn-gast-237153-merged.pdf

3. RADS—Rådet for Anvendelse af Dyr Sygehusmedicin. Baggrundsnotat for biologiske og syntetiske targetterede lægemidler til behandling af juvenil idiopatisk artritis (JIA) [The council for use of expensive hospital medication: background information on biological and synthetic targeted drugs for the use of juvenile arthritis]. RADS; 2017 [cited 2024 Apr 19]. Available from: https://rads.dk/media/4356/bgn-jia-31-237705.pdf

4. RADS—Rådet for Anvendelse af Dyr Sygehusmedicin. Baggrundsnotat for biologiske og syntetiske targeterede lægemidler til behandlinger af aksiale spondylartropatier (aSPA) [The council for use of expensive hospital medication: background information on biological and synthetic targeted drugs for the use of spondyloarthropathy]. RADS; 2017 [cited 2024 Apr 19]. Available from: https://rads.dk/media/4362/bgn-aspa-31-237690.pdf

5. RADS—Rådet for Anvendelse af Dyr Sygehusmedicin. Baggrundsnotat for biologiske og syntetiske targeterede lægemidler til behandling af Reumatoid Artritis (RA) [The council for use of expensive hospital medication: background information on biological and synthetic targeted drugs for the use of rheumatoid arthritis]. RADS; 2017 [cited 2024 Apr 19]. Available from: https://rads.dk/media/4360/bgn-ra-31-237689.pdf